[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献

[Comparison of IPSS-R and IPSS-M in newly diagnosed myelodysplastic neoplasms: a single-center study].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.7

Shunsuke Otsuki, Seiichiro Katagiri, Yuya Arai, Shohei Wakamatsu, Mituru Moriyama, Akiko Yamada, Tamiko Suguro, Michiyo Asano, Seiichiro Yoshizawa, Daigo Akahane, Yuko Tanaka, Nahoko Furuya, Hiroaki Fujimoto, Seiichi Okabe, Moritaka Gotoh, Yoshikazu Ito, Hironori Harada, Yuka Harada, Akihiko Gotoh

{"title":"[Comparison of IPSS-R and IPSS-M in newly diagnosed myelodysplastic neoplasms: a single-center study].","authors":"Shunsuke Otsuki, Seiichiro Katagiri, Yuya Arai, Shohei Wakamatsu, Mituru Moriyama, Akiko Yamada, Tamiko Suguro, Michiyo Asano, Seiichiro Yoshizawa, Daigo Akahane, Yuko Tanaka, Nahoko Furuya, Hiroaki Fujimoto, Seiichi Okabe, Moritaka Gotoh, Yoshikazu Ito, Hironori Harada, Yuka Harada, Akihiko Gotoh","doi":"10.11406/rinketsu.66.7","DOIUrl":"https://doi.org/10.11406/rinketsu.66.7","url":null,"abstract":"We compared the International Prognostic Scoring System-Revised (IPSS-R) to the International Prognostic Scoring System-Molecular (IPSS-M) in 30 patients with myelodysplastic neoplasms (MDS) newly diagnosed at our institution from January 2021 to February 2023. Molecular analysis was performed by myeloid panel. The median age was 66 years (range: 35-80), and classifications were MDS-LB (n=18), MDS IB-1 (n=1), MDS IB-2 (n=2), MDS-SF3B1 (n=2), MDS-biTP53 (n=1), and MN-pCT (n=6). Each patient had 0 to 8 (median 1) mutations. The most frequently detected mutation was the TET2 mutation, and others detected in>5 patients were U2AF1, TP53, and RUNX1 mutations. IPSS-R classification indicated that 2, 14, 5, 3, and 6 patients were very low, low, intermediate (Int), high, and very high risk, respectively, whereas the IPSS-M classification indicated that 3, 9, 7, 2, 4, and 5 cases were very low, low, moderate-low (ML), moderate-high (MH), high, and very high risk, respectively. Considering IPSS-M ML and MH as the equivalent to IPSS-R Int, 13 (43%) patients had a different risk level in the IPSS-M compared to the IPSS-R. One patient was rated low-risk by IPSS-R, but reclassified as high risk by IPSS-M. It is important to be mindful of this potential for significant discrepancies between risk assessments using IPSS-R and IPSS-M in some cases when making treatment decisions.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"7-11"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Clinical features of three cases with primary bone marrow lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.42

Hidetaka Nakagaki, Takahiro Shima, Reiko Yoneda, Masayasu Hayashi, Sae Utsumi, Seiya Hirakawa, Chiaki Kubara, Ken Takigawa, Akihisa Yoshino, Mariko Minami, Yayoi Matsuo, Takuro Kuriyama, Shuichi Taniguchi, Tetsuya Eto

{"title":"[Clinical features of three cases with primary bone marrow lymphoma].","authors":"Hidetaka Nakagaki, Takahiro Shima, Reiko Yoneda, Masayasu Hayashi, Sae Utsumi, Seiya Hirakawa, Chiaki Kubara, Ken Takigawa, Akihisa Yoshino, Mariko Minami, Yayoi Matsuo, Takuro Kuriyama, Shuichi Taniguchi, Tetsuya Eto","doi":"10.11406/rinketsu.66.42","DOIUrl":"https://doi.org/10.11406/rinketsu.66.42","url":null,"abstract":"Primary bone marrow lymphoma (PBML) is a malignant lymphoma characterized by proliferation of lymphoma cells exclusively in the bone marrow without lymphadenopathy. Despite the dismal prognosis of PBML, it is a very rare lymphoma with limited evidence concerning its pathophysiology, making accumulation of cases important. We herein report three cases of PBML at our institution. The first patient was an 80-year-old man who presented with hemophagocytic syndrome and pancytopenia at admission, and died of septic shock during initial chemotherapy. The second patient was a 64-year-old man who achieved complete remission with intensive chemotherapies, but relapsed shortly after completing the final chemotherapy course. The third patient was a 66-year-old woman who underwent chemotherapies and allogeneic hematopoietic stem cell transplantation, only to relapse shortly after transplantation. Although early intervention with chemotherapy is essential for PBML treatment, diagnosis of PBML is very challenging due to the absence of lymph node involvement. Moreover, treatment outcomes of existing chemotherapy and transplantation therapies for PBML are still poor. Further accumulation of cases and development of new treatment strategies are desirable.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"42-48"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Prophylactic efficacy of tixagevimab/cilgavimab in patients with hematological neoplasms: a single-center study].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.3

Hirofumi Nakano, Shiori Nakashima, Yui Imai, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.71

引用次数: 0

[Long-term remission achieved with allogeneic hematopoietic stem cell transplantation at first complete remission in a pediatric patient with TCF7::SPI1 fusion-positive T-cell acute lymphoblastic leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.49

Mayuko Noguchi, Kai Yamasaki, Sakiko Azuma, Natsumi Kikuchi, Chika Nitani, Keiko Okada, Nobutaka Kiyokawa, Kiyotaka Isobe, Junko Takita, Hiroyuki Fujisaki, Junichi Hara

{"title":"[Long-term remission achieved with allogeneic hematopoietic stem cell transplantation at first complete remission in a pediatric patient with TCF7::SPI1 fusion-positive T-cell acute lymphoblastic leukemia].","authors":"Mayuko Noguchi, Kai Yamasaki, Sakiko Azuma, Natsumi Kikuchi, Chika Nitani, Keiko Okada, Nobutaka Kiyokawa, Kiyotaka Isobe, Junko Takita, Hiroyuki Fujisaki, Junichi Hara","doi":"10.11406/rinketsu.66.49","DOIUrl":"https://doi.org/10.11406/rinketsu.66.49","url":null,"abstract":"T-cell acute lymphocytic leukemia (T-ALL) with SPI1 fusion, a leukemia subtype first identified in Japan, has a very poor prognosis. A 7-year-old boy was admitted to our hospital with fever, cervical lymphadenopathy, eyelid edema, and purpura. White blood cell count was markedly increased (551,000/µl). Flow cytometric analysis revealed cyCD3, CD1a, CD8, and HLA-DR positive T-ALL, and fusion gene screening identified TCF7::SPI1 fusion. The patient was treated according to the JPLSG ALL-T11 protocol. He responded poorly to prednisolone, but favorably to L-asparaginase. After completion of early intensification therapy, molecular remission was confirmed. However, due to the patient's poor response to prednisolone, and the presence of the SPI1 fusion gene, hematopoietic stem cell transplantation from an HLA-matched unrelated donor was performed in first remission. So far, the patient has been in remission for 36 months from the time of onset. Hematopoietic stem cell transplantation in first remission may be effective treatment for patients with T-ALL and SPI1 fusion.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"49-53"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Diffuse large B-cell lymphoma with central pontine myelinolysis without rapid changes in serum sodium levels].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.30

Aika Kitamura, Makoto Osada, Hisako Kunieda, Yuiko Tsukada, Soya Iwamoto, Koichi Oki, Takahide Kikuchi, Kohei Yamazaki

{"title":"[Diffuse large B-cell lymphoma with central pontine myelinolysis without rapid changes in serum sodium levels].","authors":"Aika Kitamura, Makoto Osada, Hisako Kunieda, Yuiko Tsukada, Soya Iwamoto, Koichi Oki, Takahide Kikuchi, Kohei Yamazaki","doi":"10.11406/rinketsu.66.30","DOIUrl":"https://doi.org/10.11406/rinketsu.66.30","url":null,"abstract":"Central pontine myelinolysis (CPM) typically arises from the rapid correction of hyponatremia. A literature search showed that CPM secondary to malignant lymphoma is rare, with only 11 reported cases. An 80-year-old woman presented with anorexia as her primary symptom and was subsequently diagnosed with diffuse large B-cell lymphoma (DLBCL) following an axillary lymph node biopsy. Shortly after treatment initiation, she experienced convulsions and altered consciousness. Brain MRI revealed a symmetrical lesion in the pons, but gadolinium enhancement was not observed and cerebrospinal fluid cytology showed negative results. Despite the absence of a history of hyponatremia, we diagnosed CPM secondary to malignant lymphoma due to the consistent MRI findings and previous similar case reports. Chemotherapy for DLBCL was continued, leading to gradual improvement of the pontine lesion and the patient's neurological status. Given the rarity of CPM secondary to malignant lymphoma, we present a summary of previously reported cases.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"30-35"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.54

引用次数: 0

[Intravascular large B-cell lymphoma presenting as subacute progressive myelopathy].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.12

Kiwamu Doi, Yosuke Nonohara, Soichiro Sakamoto, Toshiyuki Kitano

{"title":"[Intravascular large B-cell lymphoma presenting as subacute progressive myelopathy].","authors":"Kiwamu Doi, Yosuke Nonohara, Soichiro Sakamoto, Toshiyuki Kitano","doi":"10.11406/rinketsu.66.12","DOIUrl":"https://doi.org/10.11406/rinketsu.66.12","url":null,"abstract":"The clinical manifestations of intravascular large B-cell lymphoma (IVLBCL) are highly variable and include constitutional B symptoms, neurological findings, and skin lesions. We report the case of a 64-year-old male patient who presented with myelopathy as a sole manifestation of IVLBCL. He had experienced progressive bilateral leg weakness along with bladder and rectal dysfunction for several months. He did not have non-neurological symptoms such as fever, night sweats, and weight loss at presentation. Blood tests, cerebrospinal fluid analysis, random skin biopsy, and bone marrow biopsy showed no evidence of lymphoproliferative disease. Subsequently, the patient developed a fever, and his LDH and soluble interleukin-2 receptor levels were elevated. PET/CT showed ground-glass opacity of the lung with associated FDG avidity. Transbronchial lung biopsy confirmed a diagnosis of IVLBCL. The patient received 6 cycles of R-CHOP combined with 2 cycles of high-dose methotrexate. His symptoms gradually improved with the chemotherapy, and PET/CT after completion of the treatment showed a complete metabolic response.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"12-17"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Successful treatment with EPOCH followed by mogamulizumab for angioimmunoblastic T-cell lymphoma with myelofibrosis and pure red cell aplasia].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.24

Ayako Yamamura, Kisato Nosaka, Hiro Tatetsu, Jun-Ichirou Yasunaga

{"title":"[Successful treatment with EPOCH followed by mogamulizumab for angioimmunoblastic T-cell lymphoma with myelofibrosis and pure red cell aplasia].","authors":"Ayako Yamamura, Kisato Nosaka, Hiro Tatetsu, Jun-Ichirou Yasunaga","doi":"10.11406/rinketsu.66.24","DOIUrl":"https://doi.org/10.11406/rinketsu.66.24","url":null,"abstract":"The patient was a 70-year-old woman. She visited a doctor for sore throat, facial edema, and lymphadenopathy. Lymph node biopsy was performed, and led to a diagnosis of AITL. When the patient was admitted to our department for treatment, she had severe anemia with Hb 4.2 g/dl, and bone marrow aspiration resulted in a dry tap. Bone marrow biopsy revealed infiltration of tumor cells, a severe decrease in erythroblastic cells, and bone marrow fibrosis. Although lymph node size was reduced by THP-COP, bone marrow biopsy showed residual infiltration of tumor cells. In addition, since low reticulocyte counts and anemia persisted, weekly red blood cell transfusions were required. Therefore, the treatment regimen was changed to EPOCH. After two cycles of EPOCH, anemia improved, and red cell transfusions were no longer required. Bone marrow examination after four cycles showed disappearance of lymphoma cells and no evidence of bone marrow fibrosis or erythroblasts. However, due to residual bone marrow infiltration of lymphoma cells, treatment with mogamulizumab was started. Complete remission was maintained for five years. This indicates that EPOCH and mogamulizumab are treatment options for AITL patients with bone marrow involvement, PRCA, and myelofibrosis.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"24-29"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.18

Kodai Kunisada, Mizuki Ogura, Yuki Oda, Moe Yogo, Tomomi Takei, Kota Sato, Taku Kikuchi, Yu Abe, Nobuhiro Tsukada, Tadao Ishida

{"title":"[Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis].","authors":"Kodai Kunisada, Mizuki Ogura, Yuki Oda, Moe Yogo, Tomomi Takei, Kota Sato, Taku Kikuchi, Yu Abe, Nobuhiro Tsukada, Tadao Ishida","doi":"10.11406/rinketsu.66.18","DOIUrl":"https://doi.org/10.11406/rinketsu.66.18","url":null,"abstract":"[Patient] A 65-year-old man. [History of present illness] An abnormal chest shadow was noted in March of 2011, and hoarseness was observed in November of 2017. Both times, AL amyloidosis was diagnosed by biopsy. The patient was admitted to our department for treatment in March 2018, and received 6 cycles of melphalan plus dexamethasone for systemic AL amyloidosis in May. His condition was good, but a blood test in August 2019 showed white blood cells 50,000/µl and 44.9% blasts in the peripheral blood, leading to a diagnosis of treatment-related acute leukemia (AML with inv (16)(p13.1q22);CBFB::MYH11). He achieved complete remission with standard treatment, but relapsed in May 2020, CNS relapsed in September 2020, CNS relapsed again in July 2021, and CNS relapsed a third time in May 2022. He underwent intensive chemotherapy, whole brain radiation therapy, 13 rounds of intrathecal injection, and five cycles of venetoclax plus azacitidine, but his general condition gradually worsened. He was transferred to best supportive care in November and died in June 2023. [Discussion] Although advances in treatment have extended survival in systemic AL amyloidosis, long-term follow-up for secondary cancer is important for patients with long-term exposure, as in this case.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"18-23"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0